PDS Biotechnology (PDSB) Retained Earnings (2014 - 2026)
PDS Biotechnology's (PDSB) quarterly Retained Earnings came in at -$216.6 million in Q4 2025, down 207.71% YoY from $201.1 million in Q4 2024, and down 3.62% on a QoQ basis from -$209.0 million in Q3 2025.
PDS Biotechnology (PDSB) Retained Earnings (2014 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Retained Earnings data on file, last reported at -$216.6 million in Q4 2025.
- Quarterly Retained Earnings fell 207.71% year-over-year to -$216.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$216.6 million (down 207.71% YoY) and the FY2025 annual result came in at -$216.6 million, down 207.71% from the prior year.
- Retained Earnings retreated to -$216.6 million in Q4 2025, from -$209.0 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $216.0 million in Q2 2025 to a low of -$216.6 million in Q4 2025.
- A 5-year average of -$7.4 million and a median of -$61.8 million in 2021 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings surged 306.93% — and 2025, when it slumped 207.71%.
- Tracing PDSB's Retained Earnings over 5 years: stood at $123.9 million in 2021, then plunged by 181.97% to -$101.6 million in 2022, then tumbled by 42.28% to -$144.5 million in 2023, then surged by 239.17% to $201.1 million in 2024, then tumbled by 207.71% to -$216.6 million in 2025.
- The last three Retained Earnings figures came in at -$216.6 million (Q4 2025), -$209.0 million (Q3 2025), and $216.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.95 Bn | 132.10 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.71 Bn | 60.52 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.45 Bn | 55.31 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.24 Bn | 37.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.64 Bn | 10.25 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 4.38 Bn |
| 10 | PDS Biotechnology | 12.71 Mn | 12.71 Mn | - | -233.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -233.71 Mn |
| Dec 31, 2025 | -216.61 Mn |
| Sep 30, 2025 | -209.04 Mn |
| Jun 30, 2025 | 215.98 Mn |
| Mar 31, 2025 | 212.95 Mn |
| Dec 31, 2024 | 201.10 Mn |
| Sep 30, 2024 | 196.15 Mn |
| Jun 30, 2024 | 194.34 Mn |
| Mar 31, 2024 | -155.10 Mn |
| Dec 31, 2023 | -144.50 Mn |
| Sep 30, 2023 | -133.60 Mn |
| Jun 30, 2023 | 155.19 Mn |
| Mar 31, 2023 | -111.22 Mn |
| Dec 31, 2022 | -101.56 Mn |
| Sep 30, 2022 | -82.42 Mn |
| Jun 30, 2022 | -75.00 Mn |
| Mar 31, 2022 | -69.18 Mn |
| Dec 31, 2021 | 123.90 Mn |
| Sep 30, 2021 | -54.38 Mn |
| Jun 30, 2021 | -47.42 Mn |